Cubist Systematic Strategies LLC bought a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,143 shares of the medical instruments supplier’s stock, valued at approximately $40,000.
Several other institutional investors also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Harvard Bioscience during the 2nd quarter worth $31,000. Price T Rowe Associates Inc. MD bought a new stake in Harvard Bioscience during the first quarter valued at about $54,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Harvard Bioscience in the first quarter valued at about $112,000. Gabelli Funds LLC bought a new position in shares of Harvard Bioscience in the second quarter worth about $128,000. Finally, Rhumbline Advisers boosted its stake in Harvard Bioscience by 24.9% during the 2nd quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock valued at $136,000 after purchasing an additional 9,512 shares during the period. 80.87% of the stock is currently owned by institutional investors.
Harvard Bioscience Stock Performance
Shares of NASDAQ HBIO opened at $2.40 on Wednesday. Harvard Bioscience, Inc. has a 12 month low of $2.38 and a 12 month high of $5.56. The company has a market cap of $104.23 million, a P/E ratio of -12.05 and a beta of 1.29. The business’s 50 day moving average is $2.83 and its two-hundred day moving average is $3.23. The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.48.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Featured Articles
- Five stocks we like better than Harvard Bioscience
- What is a Death Cross in Stocks?
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- The 3 Best Blue-Chip Stocks to Buy Now
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.